Pictet Asset Management (Switzerland)’s PTC Therapeutics PTCT Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$27.9M	Buy	686,450 +176,918	+35%	+$8.66M	0.03%	388
2023 Q1	$24.7M	Buy	509,532 +343,911	+208%	+$15.7M	0.03%	419
2022 Q4	$6.32M	Buy	165,621 +43,862	+36%	+$1.82M	0.01%	697
2022 Q3	$6.11M	Buy	121,759 +37,035	+44%	+$1.81M	0.01%	685
2022 Q2	$3.39M	Buy	+84,724	New	+$2.97M	﹤0.01%	844

Other funds holding PTCT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s PTCT Position: Q2 2023 in Review

Pictet Asset Management (Switzerland) increased its PTC Therapeutics (PTCT) stake by 35% in Q2 2023, buying an estimated $8.66M and bringing the position to 686,450 shares worth $27.9M. The position accounts for 0.03% of the portfolio, ranked #388.

Pictet Asset Management (Switzerland) first reported a position in PTCT in Q2 2022 and has held it in 5 quarters since. 205 funds tracked by Wall St. Rank hold PTCT as of Q2 2023.

Pictet Asset Management (Switzerland) held 686,450 shares of PTC Therapeutics worth $27.9M as of Q2 2023.
Pictet Asset Management (Switzerland) bought 176,918 PTC Therapeutics shares in Q2 2023, an estimated $8.66M.
PTC Therapeutics made up 0.03% of Pictet Asset Management (Switzerland)'s portfolio in Q2 2023, its #388 holding.
Pictet Asset Management (Switzerland) first reported a position in PTC Therapeutics in Q2 2022 and has held it in 5 quarters since.
205 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2023.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 10 Aug 2023.